Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry
To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA). The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the freq...
Gespeichert in:
| Veröffentlicht in: | Rheumatology 2017-04, Vol.56 (4), p.629-637 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 637 |
|---|---|
| container_issue | 4 |
| container_start_page | 629 |
| container_title | Rheumatology |
| container_volume | 56 |
| creator | Latourte, Augustin Gottenberg, Jacques-Eric Luxembourger, Cécile Pane, Isabelle Claudepierre, Pascal Richette, Pascal Lafforgue, Pierre Combe, Bernard Cantagrel, Alain Sibilia, Jean Flipo, René-Marc Gaudin, Philippe Vittecoq, Olivier Schaeverbeke, Thierry Dougados, Maxime Sellam, Jeremie Ravaud, Philippe Mariette, Xavier Seror, Raphaèle |
| description | To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA).
The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications.
We identified 205 (20.3%) patients who underwent 263 surgeries, including 176 (66.9%) orthopaedic surgeries. Nineteen (7.2%) surgeries, in 19 patients (9.3%), entailed complications, including 7 delayed wound healing (2.7% of surgeries) and 6 surgical site infections (2.3% of surgeries). The median time between the last infusion of ABA and surgery was 5.9 weeks (range: 0.3-12.0 weeks), with no significant difference between patients with and without complications. The median corticosteroids daily dosage was higher in the group with complications [10.0 (6.25-15.0) vs 6.0 (5.0-10.0) mg/day, P = 0.042]. In multivariate analysis, only the duration of ABA treatment was significantly associated with postoperative complications [adjusted odds ratio (aOR) = 0.94 (95% CI: 0.89, 0.99) for each month of treatment], as were orthopaedic surgeries compared with other kinds of surgery [aOR = 4.45 (95% CI: 1.01, 20.2)].
In RA patients treated with ABA, the rate of surgical complications was low: 7.2% and higher in case of orthopaedic procedure and a more recent initiation of ABA. The median time between surgery and the last infusion of ABA was short and did not influence the rate of postoperative complications. |
| doi_str_mv | 10.1093/rheumatology/kew476 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01792710v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1855786883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-cf459794fe965c2afb6ebd11296de3c5a3dc63025511ec1a60b290a3205d28153</originalsourceid><addsrcrecordid>eNpNkUlPwzAUhC0EgrL8AiTkIxwKXuIs3KqKTapUieVsvTgvjSFpiu2A8hv406QqFE5v9DTzzWEIOeXskrNMXrkKuwZCW7eL_uoNP6Mk3iEjHsVizKQUu1stogNy6P0rY0xxme6TA5EyJUUSjcjXE5QYetqW1Hduga6ndklXECwug6efNlT0t8gWFFyonA3W0-AQAhY07ynkEMDgKlzTYlC0dG1DQ4X01uHSVHS-PhbW4Mc_1GSLesSF9cH1x2SvhNrjyc89Ii-3N8_T-_FsfvcwnczGRqZRGJsyUlmSRSVmsTICyjzGvOBcZHGB0iiQhYklE0pxjoZDzHKRMZCCqUKkXMkjcrHhVlDrlbMNuF63YPX9ZKbXP8aTTCScffDBe77xrlz73qEPurHeYF3DEtvOa54qlaRxmsrBKjdW41rvHZZbNmd6vZj-v5jeLDakzn4KurzBYpv5nUh-A3qQmKc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1855786883</pqid></control><display><type>article</type><title>Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Latourte, Augustin ; Gottenberg, Jacques-Eric ; Luxembourger, Cécile ; Pane, Isabelle ; Claudepierre, Pascal ; Richette, Pascal ; Lafforgue, Pierre ; Combe, Bernard ; Cantagrel, Alain ; Sibilia, Jean ; Flipo, René-Marc ; Gaudin, Philippe ; Vittecoq, Olivier ; Schaeverbeke, Thierry ; Dougados, Maxime ; Sellam, Jeremie ; Ravaud, Philippe ; Mariette, Xavier ; Seror, Raphaèle</creator><creatorcontrib>Latourte, Augustin ; Gottenberg, Jacques-Eric ; Luxembourger, Cécile ; Pane, Isabelle ; Claudepierre, Pascal ; Richette, Pascal ; Lafforgue, Pierre ; Combe, Bernard ; Cantagrel, Alain ; Sibilia, Jean ; Flipo, René-Marc ; Gaudin, Philippe ; Vittecoq, Olivier ; Schaeverbeke, Thierry ; Dougados, Maxime ; Sellam, Jeremie ; Ravaud, Philippe ; Mariette, Xavier ; Seror, Raphaèle</creatorcontrib><description>To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA).
The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications.
We identified 205 (20.3%) patients who underwent 263 surgeries, including 176 (66.9%) orthopaedic surgeries. Nineteen (7.2%) surgeries, in 19 patients (9.3%), entailed complications, including 7 delayed wound healing (2.7% of surgeries) and 6 surgical site infections (2.3% of surgeries). The median time between the last infusion of ABA and surgery was 5.9 weeks (range: 0.3-12.0 weeks), with no significant difference between patients with and without complications. The median corticosteroids daily dosage was higher in the group with complications [10.0 (6.25-15.0) vs 6.0 (5.0-10.0) mg/day, P = 0.042]. In multivariate analysis, only the duration of ABA treatment was significantly associated with postoperative complications [adjusted odds ratio (aOR) = 0.94 (95% CI: 0.89, 0.99) for each month of treatment], as were orthopaedic surgeries compared with other kinds of surgery [aOR = 4.45 (95% CI: 1.01, 20.2)].
In RA patients treated with ABA, the rate of surgical complications was low: 7.2% and higher in case of orthopaedic procedure and a more recent initiation of ABA. The median time between surgery and the last infusion of ABA was short and did not influence the rate of postoperative complications.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>EISSN: 1460-2172</identifier><identifier>DOI: 10.1093/rheumatology/kew476</identifier><identifier>PMID: 28053274</identifier><language>eng</language><publisher>England: Oxford University Press (OUP)</publisher><subject>Abatacept - adverse effects ; Antirheumatic Agents - administration & dosage ; Arthritis, Rheumatoid - drug therapy ; Female ; France ; Human health and pathology ; Humans ; Life Sciences ; Male ; Middle Aged ; Orthopedic Procedures - adverse effects ; Patient Safety ; Postoperative Complications - chemically induced ; Prospective Studies ; Registries ; Rhumatology and musculoskeletal system ; Risk Factors ; Surgical Wound Infection - chemically induced ; Time Factors ; Wound Healing - drug effects</subject><ispartof>Rheumatology, 2017-04, Vol.56 (4), p.629-637</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-cf459794fe965c2afb6ebd11296de3c5a3dc63025511ec1a60b290a3205d28153</citedby><cites>FETCH-LOGICAL-c384t-cf459794fe965c2afb6ebd11296de3c5a3dc63025511ec1a60b290a3205d28153</cites><orcidid>0000-0002-9469-946X ; 0000-0003-2132-4074 ; 0000-0001-5528-8070 ; 0000-0002-5523-1856 ; 0000-0002-4244-5417 ; 0000-0002-1087-7768 ; 0000-0002-6976-643X ; 0000-0001-8264-9206</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28053274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01792710$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Latourte, Augustin</creatorcontrib><creatorcontrib>Gottenberg, Jacques-Eric</creatorcontrib><creatorcontrib>Luxembourger, Cécile</creatorcontrib><creatorcontrib>Pane, Isabelle</creatorcontrib><creatorcontrib>Claudepierre, Pascal</creatorcontrib><creatorcontrib>Richette, Pascal</creatorcontrib><creatorcontrib>Lafforgue, Pierre</creatorcontrib><creatorcontrib>Combe, Bernard</creatorcontrib><creatorcontrib>Cantagrel, Alain</creatorcontrib><creatorcontrib>Sibilia, Jean</creatorcontrib><creatorcontrib>Flipo, René-Marc</creatorcontrib><creatorcontrib>Gaudin, Philippe</creatorcontrib><creatorcontrib>Vittecoq, Olivier</creatorcontrib><creatorcontrib>Schaeverbeke, Thierry</creatorcontrib><creatorcontrib>Dougados, Maxime</creatorcontrib><creatorcontrib>Sellam, Jeremie</creatorcontrib><creatorcontrib>Ravaud, Philippe</creatorcontrib><creatorcontrib>Mariette, Xavier</creatorcontrib><creatorcontrib>Seror, Raphaèle</creatorcontrib><title>Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry</title><title>Rheumatology</title><addtitle>Rheumatology (Oxford)</addtitle><description>To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA).
The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications.
We identified 205 (20.3%) patients who underwent 263 surgeries, including 176 (66.9%) orthopaedic surgeries. Nineteen (7.2%) surgeries, in 19 patients (9.3%), entailed complications, including 7 delayed wound healing (2.7% of surgeries) and 6 surgical site infections (2.3% of surgeries). The median time between the last infusion of ABA and surgery was 5.9 weeks (range: 0.3-12.0 weeks), with no significant difference between patients with and without complications. The median corticosteroids daily dosage was higher in the group with complications [10.0 (6.25-15.0) vs 6.0 (5.0-10.0) mg/day, P = 0.042]. In multivariate analysis, only the duration of ABA treatment was significantly associated with postoperative complications [adjusted odds ratio (aOR) = 0.94 (95% CI: 0.89, 0.99) for each month of treatment], as were orthopaedic surgeries compared with other kinds of surgery [aOR = 4.45 (95% CI: 1.01, 20.2)].
In RA patients treated with ABA, the rate of surgical complications was low: 7.2% and higher in case of orthopaedic procedure and a more recent initiation of ABA. The median time between surgery and the last infusion of ABA was short and did not influence the rate of postoperative complications.</description><subject>Abatacept - adverse effects</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Female</subject><subject>France</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Orthopedic Procedures - adverse effects</subject><subject>Patient Safety</subject><subject>Postoperative Complications - chemically induced</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Rhumatology and musculoskeletal system</subject><subject>Risk Factors</subject><subject>Surgical Wound Infection - chemically induced</subject><subject>Time Factors</subject><subject>Wound Healing - drug effects</subject><issn>1462-0324</issn><issn>1462-0332</issn><issn>1460-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkUlPwzAUhC0EgrL8AiTkIxwKXuIs3KqKTapUieVsvTgvjSFpiu2A8hv406QqFE5v9DTzzWEIOeXskrNMXrkKuwZCW7eL_uoNP6Mk3iEjHsVizKQUu1stogNy6P0rY0xxme6TA5EyJUUSjcjXE5QYetqW1Hduga6ndklXECwug6efNlT0t8gWFFyonA3W0-AQAhY07ynkEMDgKlzTYlC0dG1DQ4X01uHSVHS-PhbW4Mc_1GSLesSF9cH1x2SvhNrjyc89Ii-3N8_T-_FsfvcwnczGRqZRGJsyUlmSRSVmsTICyjzGvOBcZHGB0iiQhYklE0pxjoZDzHKRMZCCqUKkXMkjcrHhVlDrlbMNuF63YPX9ZKbXP8aTTCScffDBe77xrlz73qEPurHeYF3DEtvOa54qlaRxmsrBKjdW41rvHZZbNmd6vZj-v5jeLDakzn4KurzBYpv5nUh-A3qQmKc</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Latourte, Augustin</creator><creator>Gottenberg, Jacques-Eric</creator><creator>Luxembourger, Cécile</creator><creator>Pane, Isabelle</creator><creator>Claudepierre, Pascal</creator><creator>Richette, Pascal</creator><creator>Lafforgue, Pierre</creator><creator>Combe, Bernard</creator><creator>Cantagrel, Alain</creator><creator>Sibilia, Jean</creator><creator>Flipo, René-Marc</creator><creator>Gaudin, Philippe</creator><creator>Vittecoq, Olivier</creator><creator>Schaeverbeke, Thierry</creator><creator>Dougados, Maxime</creator><creator>Sellam, Jeremie</creator><creator>Ravaud, Philippe</creator><creator>Mariette, Xavier</creator><creator>Seror, Raphaèle</creator><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-9469-946X</orcidid><orcidid>https://orcid.org/0000-0003-2132-4074</orcidid><orcidid>https://orcid.org/0000-0001-5528-8070</orcidid><orcidid>https://orcid.org/0000-0002-5523-1856</orcidid><orcidid>https://orcid.org/0000-0002-4244-5417</orcidid><orcidid>https://orcid.org/0000-0002-1087-7768</orcidid><orcidid>https://orcid.org/0000-0002-6976-643X</orcidid><orcidid>https://orcid.org/0000-0001-8264-9206</orcidid></search><sort><creationdate>20170401</creationdate><title>Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry</title><author>Latourte, Augustin ; Gottenberg, Jacques-Eric ; Luxembourger, Cécile ; Pane, Isabelle ; Claudepierre, Pascal ; Richette, Pascal ; Lafforgue, Pierre ; Combe, Bernard ; Cantagrel, Alain ; Sibilia, Jean ; Flipo, René-Marc ; Gaudin, Philippe ; Vittecoq, Olivier ; Schaeverbeke, Thierry ; Dougados, Maxime ; Sellam, Jeremie ; Ravaud, Philippe ; Mariette, Xavier ; Seror, Raphaèle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-cf459794fe965c2afb6ebd11296de3c5a3dc63025511ec1a60b290a3205d28153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abatacept - adverse effects</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Female</topic><topic>France</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Orthopedic Procedures - adverse effects</topic><topic>Patient Safety</topic><topic>Postoperative Complications - chemically induced</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Rhumatology and musculoskeletal system</topic><topic>Risk Factors</topic><topic>Surgical Wound Infection - chemically induced</topic><topic>Time Factors</topic><topic>Wound Healing - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Latourte, Augustin</creatorcontrib><creatorcontrib>Gottenberg, Jacques-Eric</creatorcontrib><creatorcontrib>Luxembourger, Cécile</creatorcontrib><creatorcontrib>Pane, Isabelle</creatorcontrib><creatorcontrib>Claudepierre, Pascal</creatorcontrib><creatorcontrib>Richette, Pascal</creatorcontrib><creatorcontrib>Lafforgue, Pierre</creatorcontrib><creatorcontrib>Combe, Bernard</creatorcontrib><creatorcontrib>Cantagrel, Alain</creatorcontrib><creatorcontrib>Sibilia, Jean</creatorcontrib><creatorcontrib>Flipo, René-Marc</creatorcontrib><creatorcontrib>Gaudin, Philippe</creatorcontrib><creatorcontrib>Vittecoq, Olivier</creatorcontrib><creatorcontrib>Schaeverbeke, Thierry</creatorcontrib><creatorcontrib>Dougados, Maxime</creatorcontrib><creatorcontrib>Sellam, Jeremie</creatorcontrib><creatorcontrib>Ravaud, Philippe</creatorcontrib><creatorcontrib>Mariette, Xavier</creatorcontrib><creatorcontrib>Seror, Raphaèle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Latourte, Augustin</au><au>Gottenberg, Jacques-Eric</au><au>Luxembourger, Cécile</au><au>Pane, Isabelle</au><au>Claudepierre, Pascal</au><au>Richette, Pascal</au><au>Lafforgue, Pierre</au><au>Combe, Bernard</au><au>Cantagrel, Alain</au><au>Sibilia, Jean</au><au>Flipo, René-Marc</au><au>Gaudin, Philippe</au><au>Vittecoq, Olivier</au><au>Schaeverbeke, Thierry</au><au>Dougados, Maxime</au><au>Sellam, Jeremie</au><au>Ravaud, Philippe</au><au>Mariette, Xavier</au><au>Seror, Raphaèle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry</atitle><jtitle>Rheumatology</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>56</volume><issue>4</issue><spage>629</spage><epage>637</epage><pages>629-637</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><eissn>1460-2172</eissn><abstract>To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA).
The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications.
We identified 205 (20.3%) patients who underwent 263 surgeries, including 176 (66.9%) orthopaedic surgeries. Nineteen (7.2%) surgeries, in 19 patients (9.3%), entailed complications, including 7 delayed wound healing (2.7% of surgeries) and 6 surgical site infections (2.3% of surgeries). The median time between the last infusion of ABA and surgery was 5.9 weeks (range: 0.3-12.0 weeks), with no significant difference between patients with and without complications. The median corticosteroids daily dosage was higher in the group with complications [10.0 (6.25-15.0) vs 6.0 (5.0-10.0) mg/day, P = 0.042]. In multivariate analysis, only the duration of ABA treatment was significantly associated with postoperative complications [adjusted odds ratio (aOR) = 0.94 (95% CI: 0.89, 0.99) for each month of treatment], as were orthopaedic surgeries compared with other kinds of surgery [aOR = 4.45 (95% CI: 1.01, 20.2)].
In RA patients treated with ABA, the rate of surgical complications was low: 7.2% and higher in case of orthopaedic procedure and a more recent initiation of ABA. The median time between surgery and the last infusion of ABA was short and did not influence the rate of postoperative complications.</abstract><cop>England</cop><pub>Oxford University Press (OUP)</pub><pmid>28053274</pmid><doi>10.1093/rheumatology/kew476</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9469-946X</orcidid><orcidid>https://orcid.org/0000-0003-2132-4074</orcidid><orcidid>https://orcid.org/0000-0001-5528-8070</orcidid><orcidid>https://orcid.org/0000-0002-5523-1856</orcidid><orcidid>https://orcid.org/0000-0002-4244-5417</orcidid><orcidid>https://orcid.org/0000-0002-1087-7768</orcidid><orcidid>https://orcid.org/0000-0002-6976-643X</orcidid><orcidid>https://orcid.org/0000-0001-8264-9206</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology, 2017-04, Vol.56 (4), p.629-637 |
| issn | 1462-0324 1462-0332 1460-2172 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01792710v1 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Abatacept - adverse effects Antirheumatic Agents - administration & dosage Arthritis, Rheumatoid - drug therapy Female France Human health and pathology Humans Life Sciences Male Middle Aged Orthopedic Procedures - adverse effects Patient Safety Postoperative Complications - chemically induced Prospective Studies Registries Rhumatology and musculoskeletal system Risk Factors Surgical Wound Infection - chemically induced Time Factors Wound Healing - drug effects |
| title | Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A51%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20surgery%20in%20patients%20with%20rheumatoid%20arthritis%20treated%20by%20abatacept:%20data%20from%20the%20French%20Orencia%20in%20Rheumatoid%20Arthritis%20Registry&rft.jtitle=Rheumatology&rft.au=Latourte,%20Augustin&rft.date=2017-04-01&rft.volume=56&rft.issue=4&rft.spage=629&rft.epage=637&rft.pages=629-637&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kew476&rft_dat=%3Cproquest_hal_p%3E1855786883%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1855786883&rft_id=info:pmid/28053274&rfr_iscdi=true |